Single Use of Sumatriptan: A Patient Interview Study
Article first published online: 31 JAN 2003
Headache: The Journal of Head and Face Pain
Volume 43, Issue 2, pages 109–116, February 2003
How to Cite
Rahimtoola, H., Buurma, H., Tijssen, C.C., Leufkens, H.G. and Egberts, A.C.G. (2003), Single Use of Sumatriptan: A Patient Interview Study. Headache: The Journal of Head and Face Pain, 43: 109–116. doi: 10.1046/j.1526-4610.2003.03027.x
- Issue published online: 31 JAN 2003
- Article first published online: 31 JAN 2003
- Accepted for publication August 30, 2002.
- single recipient;
Objective.—To investigate the possible reasons associated with the use of a single prescription of sumatriptan.
Background.—A few population-based studies concerning the usage patterns of sumatriptan have revealed a relatively high incidence (approximately 40%) of sumatriptan users who utilize only a single prescription of the drug.
Design and Methods.—Using automated prescription data from 11 community pharmacies, we identified single and multiple sumatriptan prescription recipients. The data were collected from May 1, 1998, to April 30, 2000. Several patient- and medication-related variables possibly associated with single recipiency of sumatriptan were analyzed. In addition, single recipients of sumatriptan were invited for an interview and asked a number of questions related to their clinical status and their experience with the medication.
Results.—Four hundred ninety-five, first-time users of sumatriptan were identified during the patient selection period, of whom 38% were single recipients of sumatriptan. Of the latter, 102 patients were considered eligible for interview. Reasons for terminating treatment after only 1 prescription included: inefficacy and/or occurrence of side effects, 78% (n = 79); uncertain diagnosis of migraine, 39.2% (n = 40); and reduction in headache frequency, 33.3% (n = 34). Almost half of the population had terminated treatment without having consulted their physician. More than half relied upon the use of over-the-counter (OTC) analgesics after having tried sumatriptan. Compared to multiple users of sumatriptan, single recipients were far less likely to have used another form of migraine treatment prior to (odds ratio, 0.35; [95% confidence interval, 019 to 0.67]) and after (odds ratio, 0.34 [95% confidence interval, 0.19 to 0.63]) initiating sumatriptan. Furthermore, single recipients had demonstrated an increased tendency towards benzodiazepine use prior to receiving sumatriptan (odds ratio, 1.80 [95% confidence interval, 1.00 to 3.28]).
Conclusions.—Single use of a sumatriptan prescription reveals some issues that may impact negatively the provision of effective migraine management. These include: rapidly developing dissatisfaction with the treatment provided and a lower tendency to seek out medical care. Our results also suggest that the drug may be used (inappropriately) as a diagnostic tool.